Home / Executive Moves / CMS, Lockheed Vet Karen Shields Named Serco Inc. Health Sector VP; Dave Dacquino Comments

CMS, Lockheed Vet Karen Shields Named Serco Inc. Health Sector VP; Dave Dacquino Comments

Karen Shields

Karen Shields, a Centers for Medicare and Medicaid Services veteran, has been appointed vice president of health sector at Serco Inc. — the British contractor’s North American arm.

She will oversee efforts to grow a portfolio of consulting, operational and business processing platforms designed to help customer agencies deliver healthcare services to citizens, Serco said Monday.

Dave Dacquino

Dave Dacquino, Serco Inc. chairman and CEO, said Shields’ knowledge of government operations and policies and thought leadership would help the company pursue growth opportunities in the health care services sector.

Shields has more than three decades of leadership experience in both public and private sectors and previously served as deputy director of CMS’ center for consumer information and insurance oversight.

She also held other leadership roles at CMS such as executive for operations, director of customer liaison and support services division and head of the consumer information insurance systems group.

Shields spent nine years as a senior support services manager at Lockheed Martin (NYSE: LMT), where she provided assistance to federal agencies.

Prior to Lockheed, she served as an assistant VP at investment management firm Legg Mason (NYSE: LM).

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.